Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer
drugs are organic molecules, while metallodrugs are very scarce. The advent of the first …

Abstract Ruthenium (II)-arene RAPTA-type compounds have been extensively explored for
their medicinal properties. Herein a comprehensive review of this class of compounds is …

The quest for alternative drugs to the well-known cisplatin and its derivatives, which are still
used in more than 50% of the treatment regimes for patients suffering from cancer, is highly …

Platinum-containing drugs (eg, cisplatin) are among the most frequently used
chemotherapeutic agents. Their tremendous success has spurred research and …

Medicinal inorganic chemistry can exploit the unique properties of metal ions for the design
of new drugs. This has, for instance, led to the clinical application of chemotherapeutic …

In undergraduate level organometallic chemistry courses students are usually taught that
organometallic compounds are toxic and unstable in air and water. While this is true of many …

Neutral or cationic arene ruthenium complexes providing both hydrophilic as well as
hydrophobic properties due to the robustness of the ruthenium–arene unit hold a high …

Interest in the medicinal properties of ruthenium (II)–arene compounds has grown rapidly
over the last decade. In this account we describe the origins of the field and subsequently …

A series of ruthenium (II)− arene (RAPTA) compounds were evaluated for their ability to
inhibit thioredoxin reductase (either cytosolic or mitochondrial) and cathepsin B, two …

A brief overview is given of platinum anticancer drugs in routine clinical use and under
clinical development worldwide. Details of the binding of these drugs with nucleic acids, the …